Zobrazeno 1 - 10
of 444
pro vyhledávání: '"Kotsa K"'
Autor:
Karras, S. N., Koufakis, T., Dimakopoulos, G., Zisimopoulou, E., Mourampetzis, P., Manthou, E., Karalazou, P., Thisiadou, K., Tsachouridou, O., Zebekakis, P., Makedou, K., Metallidis, S., Kotsa, K.
Publikováno v:
Journal of Endocrinological Investigation; Dec2023, Vol. 46 Issue 12, p2563-2571, 9p
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Current guidelines for the management of hyperglycemia recommend the use of agents with proven cardiovascular (CV) benefit in patients with type 2 diabetes (T2D) and established CV disease. Although both glucagon-like peptide 1 receptor agonists (GLP
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::2d0941e9392f846d3c515f822c7e5ab2
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3118668
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3118668
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
In Neuropeptides 2009 43(1):41-46
Introduction: Tyrosine kinase inhibitors (TKIs) have been used in patients with advanced medullary thyroid carcinoma (MTC); however, data on their effectiveness and safety are limited. The aim of this systematic review and meta-analysis was to docume
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::b846e5a53ada75ba1b6a7282bcc99825
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3102631
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3102631
Sodium-glucose co-transporter 2 inhibitors (SGLT2i) have emerged as a promising therapeutic option for hyperglycemia and its complications. However, metformin remains the first-line pharmacological treatment in most algorithms for type 2 diabetes (T2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::0b612961bf7f5d892aedbf31db7c178c
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3020471
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3020471
Efforts to unravel the pathophysiological mechanisms of type 2 diabetes (T2D) have been traditionally trapped into a metabolic perspective. However, T2D is a phenotypically and pathophysiologically heterogenous disorder, and the need for a tailored a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::9200b8ab3a191e1f3a02ca64cee7ee93
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3119491
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3119491
BACKGROUND: Type 2 diabetes mellitus is a risk factor for lower extremity arterial disease. Cilostazol expresses antiplatelet, antiinflammatory, and vasodilator actions and improves the claudication intermittent symptoms. We investigated the efficacy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::5a979a193425df15cba17353e60c7751
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3103259
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3103259